SCHEMBL6574337

SCHEMBL6574337

Cc1cc(C(=O)N(C)c2ccccc2)c(C)cc1NC(=O)CNc1ccc(C#N)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 4/20 0.41
MAPT P10636 7/20 0.41
GAA P10253 6/20 0.41
MEN1 O00255 3/20 0.41
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.39
HPGD P15428 1/20 0.39
RORC P51449 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771396 0.84 PLAU (0.49) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL6573948 0.79 ALDH1A1 (0.47) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL16208436 0.72 ALDH1A1 (0.59) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL6572911 0.72 ALDH1A1 (0.44) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL29273240 0.72 KMT2A (0.62) ALDH1A1PKMKMT2AMAPTMEN1
SCHEMBL6563594 0.71 KMT2A (0.51) ALDH1A1PKMKMT2AMAPTMEN1
SCHEMBL6563622 0.70 KMT2A (0.43) KMT2AMEN1RORCNPC1
SCHEMBL27994268 0.69 F2 (0.43) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL20941790 0.69 NOTUM (0.57) ALDH1A1PKMKMT2AMAPTGAA
SCHEMBL505830 0.69 KMT2A (0.40) ALDH1A1PKMKMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 ALDH1A1 669/4885PKM 764/4885KMT2A 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.